超音波组织消融系统市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球超音波组织消融系统市场规模达5.191亿美元，预计复合年增长率为8.7%，到2034年将达12亿美元。这一显着增长主要得益于神经系统手术频率的不断提高、超音波消融系统在非癌性疾病中的应用范围不断扩大以及设备技术的持续进步。此外，超音波消融系统在肿瘤学以外的领域也日益得到应用，例如子宫肌瘤、良性前列腺增生 (BPH)、子宫内膜异位症，甚至心律不整，从而促进了其临床应用的广泛性。这些设备的多功能性和非侵入性使其对各种医学专业领域都极具吸引力，进一步推动了市场成长。

超音波和核磁共振等即时成像系统以及便携式自动化能量调节系统的不断发展，提高了靶向精度，显着提高了这些治疗的安全性和有效性。这些创新也使这些设备更加便捷易用，并促进了其在更多医疗机构的应用。高强度聚焦超音波 (HIFU) 系统是该市场中最大的细分市场，由于其非侵入性方法以及在不损伤周围组织的情况下治疗敏感部位的能力，其受欢迎程度持续增长。

高强度聚焦超音波 (HIFU) 系统领域在 2024 年占据了 2.608 亿美元的市场份额，占据主要地位，其在大脑、前列腺和子宫等精细敏感部位的应用日益广泛。 HIFU 系统目前常用于治疗肝癌、肾臟癌和摄护腺癌等癌症，特别适用于无法或不愿接受手术的病人。在妇科领域，HIFU 因其保留子宫且非侵入性的优势，正迅速成为治疗子宫肌瘤的首选方法。此外，它在治疗帕金森氏症和特发性震颤等神经系统疾病方面也越来越受到关注，尤其是在结合 MRI 引导的情况下。

妇科领域在2024年占据了最大的市场份额，预计到2034年将达到3.706亿美元。受育龄女性子宫肌瘤和子宫内膜异位症盛行率上升的推动，该领域正经历强劲增长。随着越来越多的女性寻求非侵入性治疗方案，高强度聚焦超音波 (HIFU) 正获得显着关注，与子宫切除术和肌瘤切除术等传统手术方法相比，它提供了一种创伤性较小的选择。

2024年，美国超音波组织消融系统市场规模达1.623亿美元。由于优惠的报销政策以及人们对微创或非侵入性手术的日益青睐，此类系统的需求正在不断增长。美国医疗保健系统越来越多地采用高强度聚焦超音波（HIFU）治疗各种疾病，包括前列腺癌、子宫肌瘤和神经系统疾病，这推动了该产品的普及。即时影像技术的整合正在提高手术的准确性和安全性，同时，医疗保健提供者和设备製造商之间的合作也正在进一步扩大超音波组织消融系统在美国的应用范围。

全球超音波组织消融系统市场的主要参与者包括 FUSMobile、bioventus、BRAINSONIX、EDAP TMS、INSIGHTEC、Haifu、Soring、Verasonics、STRYKER、PROFOUND、OLYMPUS、sonablate、ASTAR 和 INTEGRA 等。在竞争激烈的超音波组织消融市场中，各公司正专注于制定策略方案，以维持并扩大市场占有率。他们积极与医疗保健提供者建立合作伙伴关係，以增强临床应用并扩大超音波系统的使用范围。主要参与者正在持续投资研发，以推出整合即时成像功能并提供更精准治疗标靶的先进设备。一些公司正在扩大产品组合，推出便携式消融系统，以满足门诊患者的需求。此外，一些製造商正致力于提高患者舒适度、缩短手术时间并加强安全规程，以使其係统对医疗保健专业人员更具吸引力。此外，这些公司还透过为临床医生和医疗保健提供者提供培训和教育项目，旨在提高采用率并建立品牌忠诚度。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
  • 供应商格局
  • 每个阶段的增值
  • 影响价值链的因素
• 产业衝击力
  • 成长动力
    • 神经系统手术发生率上升
    • 增加监管批准和报销政策
    • 非侵入性疗法日益受到青睐
    • 扩大在非癌症疾病的应用
  • 产业陷阱与挑战
    • 设备和手术成本高昂
  • 机会
    • 人工智慧与影像引导系统的集成，实现精确瞄准
    • 便携式、小型化的HIFU设备的开发
• 成长潜力分析
• 监管格局
  • 北美洲
  • 欧洲
• 技术和创新格局
  • 当前的技术趋势
  • 新兴技术
• 按产品分類的价格趋势
• 未来市场趋势
• 报销场景
  • 报销政策对市场成长的影响
• 消费者行为分析
• LIFU 的新兴和研究应用
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 全球的
  • 北美洲
  • 欧洲
  • 世界其他地区
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係和合作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：依产品类型，2021 年至 2034 年

• 主要趋势
• 高强度聚焦超音波（HIFU）系统
  • 磁振造影引导HIFU系统
  • 超音波引导HIFU系统
• 超音波手术消融系统
• 衝击波治疗系统

第六章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 妇科
• 癌症
• 心血管疾病
• 泌尿科
• 神经病学
• 其他应用

第七章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院
• 影像中心
• 门诊手术中心
• 其他最终用途

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• ASTAR
• bioventus
• BRAINSONIX
• EDAP TMS
• FUSMobile
• Haifu
• INSIGHTEC
• INTEGRA
• OLYMPUS
• PROFOUND
• sonablate
• Soring
• stryker
• THERACLION
• Verasonics

The Global Ultrasonic Tissue Ablation System Market was valued at USD 519.1 million in 2024 and is estimated to grow at a CAGR of 8.7% to reach USD 1.2 billion by 2034. This significant growth is primarily driven by the increasing frequency of neurological procedures, the expanding scope of ultrasound ablation systems in non-cancerous diseases, and ongoing advancements in device technologies. Additionally, ultrasound ablation systems are being increasingly applied outside oncology for conditions like uterine fibroids, benign prostatic hyperplasia (BPH), endometriosis, and even cardiac arrhythmias, contributing to their wider clinical use. The versatility and non-invasive nature of these devices make them highly attractive for various medical specialties, further driving market growth.

Improvements in targeting precision, bolstered by real-time imaging systems like ultrasound and MRI, as well as the development of portable and automated energy modulation systems, have significantly enhanced the safety and efficacy of these procedures. These innovations have also made the devices more accessible and user-friendly, encouraging their adoption in additional healthcare settings. High-intensity focused ultrasound (HIFU) systems, which represent the largest segment in this market, continue to gain popularity due to their non-invasive approach and ability to treat sensitive areas without damaging surrounding tissue.

The high-intensity focused ultrasound (HIFU) systems segment held a major market share of USD 260.8 million in 2024, showing increasing use in delicate and sensitive areas, including the brain, prostate, and uterus. HIFU systems are now commonly used to treat cancers such as liver, kidney, and prostate, particularly in patients who are unable or unwilling to undergo surgery. In gynecology, HIFU is rapidly becoming the preferred method for treating uterine fibroids, as it offers a uterus-preserving and non-invasive approach. Additionally, it is gaining traction for the treatment of neurological disorders like Parkinson's disease and essential tremor, especially when combined with MRI guidance.

The gynecology segment held the largest market share in 2024 and is projected to reach USD 370.6 million by 2034. This sector is experiencing robust growth driven by the rising prevalence of uterine fibroids and endometriosis among women of reproductive age. As more women seek non-invasive alternatives, high-intensity focused ultrasound (HIFU) is gaining significant traction, offering a less invasive option compared to traditional surgical methods like hysterectomy and myomectomy.

U.S. Ultrasonic Tissue Ablation System Market was valued at USD 162.3 million in 2024. Demand for these systems is rising due to favorable reimbursement policies, as well as a growing preference for minimally invasive or non-invasive procedures. The U.S. healthcare system's increasing adoption of HIFU for various indications, including prostate cancer, uterine fibroids, and neurological disorders, is driving product uptake. Integration of real-time imaging technologies is improving procedural accuracy and safety, while collaborative efforts between healthcare providers and device manufacturers are further expanding the scope of ultrasonic tissue ablation systems in the country.

Key players in the Global Ultrasonic Tissue Ablation System Market include names like FUSMobile, bioventus, BRAINSONIX, EDAP TMS, INSIGHTEC, Haifu, Soring, Verasonics, STRYKER, PROFOUND, OLYMPUS, sonablate, ASTAR, and INTEGRA. In the competitive ultrasonic tissue ablation market, companies are focusing on strategic approaches to maintain and expand their market share. Collaborations and partnerships with healthcare providers are being actively pursued to enhance clinical applications and broaden the use of ultrasonic systems. Key players are investing in continuous research and development to introduce advanced devices that integrate real-time imaging and provide more accurate treatment targeting. Expanding their product portfolios, some companies are introducing portable versions of their ablation systems to cater to outpatient settings. Moreover, several manufacturers are focusing on improving patient comfort, reducing procedure time, and enhancing safety protocols to make their systems more appealing to healthcare professionals. Additionally, by offering training and educational programs to clinicians and healthcare providers, these companies aim to increase adoption rates and build brand loyalty.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product type
  • 2.2.3 Application
  • 2.2.4 End Use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of neurological procedures
    • 3.2.1.2 Increasing regulatory approvals and reimbursement policies
    • 3.2.1.3 Increasing preference for non-invasive therapies
    • 3.2.1.4 Expanding applications in non-cancer diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of equipment and procedures
  • 3.2.3 Opportunities
    • 3.2.3.1 Integration of AI and image-guided systems for precision targeting
    • 3.2.3.2 Development of portable and compact HIFU devices
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Price trends, by product
• 3.7 Future market trends
• 3.8 Reimbursement scenario
  • 3.8.1 Impact of reimbursement policies on market growth
• 3.9 Consumer behaviour analysis
• 3.10 Emerging and investigational applications of LIFU
• 3.11 Gap analysis
• 3.12 Porter's analysis
• 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Rest of the world
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 High intensity focused ultrasound (HIFU) systems
  • 5.2.1 MR-guided HIFU systems
  • 5.2.2 Ultrasound-guided HIFU systems
• 5.3 Ultrasonic surgical ablation systems
• 5.4 Shock wave therapy systems

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Gynecology
• 6.3 Cancer
• 6.4 Cardiovascular disease
• 6.5 Urology
• 6.6 Neurology
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Imaging centers
• 7.4 Ambulatory surgical centers
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 ASTAR
• 9.2 bioventus
• 9.3 BRAINSONIX
• 9.4 EDAP TMS
• 9.5 FUSMobile
• 9.6 Haifu
• 9.7 INSIGHTEC
• 9.8 INTEGRA
• 9.9 OLYMPUS
• 9.10 PROFOUND
• 9.11 sonablate
• 9.12 Soring
• 9.13 stryker
• 9.14 THERACLION
• 9.15 Verasonics